Stay updated with breaking news from Affirm Al. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.
Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.
Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.
A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.
A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.